Curated News
By: NewsRamp Editorial Staff
November 09, 2026
Regentis Inks Exclusive Israel Distribution Deal for GelrinC
TLDR
- Regentis gains a four-year exclusive Israeli distribution deal for GelrinC, with minimum purchases and revenue expected from 2027.
- AMI Medical Technologies will commercialize GelrinC in Israel, leveraging orthopedic relationships while both firms pursue reimbursement coverage.
- The GelrinC implant offers a cell-free, off-the-shelf solution to regenerate knee cartilage, improving quality of life for patients.
- GelrinC is a degradable hydrogel implant that erodes in the knee, allowing surrounding cells to regenerate cartilage in a controlled process.
Impact - Why it Matters
This distribution agreement marks a significant step for Regentis Biomaterials in bringing its innovative GelrinC implant to the Israeli market, where it has already received regulatory approval. For patients suffering from knee cartilage damage, GelrinC offers a promising off-the-shelf solution that could potentially eliminate the need for more invasive procedures and provide a new avenue for tissue regeneration. The collaboration with AMI Medical Technologies to secure reimbursement coverage is crucial for patient access and widespread adoption. For investors, this deal signals progress in Regentis' commercialization strategy and sets the stage for potential revenue streams starting in 2027, while the company continues its Phase 3 clinical program in the U.S. market, which represents a substantial opportunity with approximately 470,000 cases annually. Overall, this news underscores Regentis' commitment to advancing regenerative medicine and improving patient outcomes in orthopedics.
Summary
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company specializing in tissue repair solutions, has announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC® in Israel. GelrinC is Regentis' proprietary implant for repairing damaged knee cartilage and has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States. Under the agreement, AMI will leverage its established relationships with orthopedic surgeons, hospitals, and clinics to support the product's commercial introduction. The deal includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027.
The companies will also collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may access the implant through private health insurance. This agreement supports Regentis' broader commercialization efforts in Europe and Israel as the company continues advancing its pivotal Phase 3 clinical program in the United States. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. It aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
For investors, the latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT. This content has been disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid investor awareness and marketing engagement. To view the full press release, visit https://ibn.fm/gk9yG.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Inks Exclusive Israel Distribution Deal for GelrinC
